Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cervical Adenocarcinoma

Cervical Adenocarcinoma

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cervical Adenocarcinoma

18 trials tracked for Cervical Adenocarcinoma: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 186 citations.

18Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 4 Phase 2 12 Phase 1 2
  1. Phase 3 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Completed · 186 cited
  2. Phase 3 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Completed · 40 cited
  3. Phase 3 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed
  4. Phase 3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed
  5. Phase 2 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed
  6. Phase 2 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
Show 12 more trials
  1. Phase 2 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  2. Phase 2 Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  3. Phase 2 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed
  4. Phase 2 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed
  5. Phase 2 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer Completed
  6. Phase 2 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed
  7. Phase 2 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed
  8. Phase 2 FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer Completed
  9. Phase 2 Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Completed
  10. Phase 2 Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer Completed
  11. Phase 1 Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Completed
  12. Phase 1 Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma
Oncology Meta-analysis
Systematic review and meta-analysis of survival outcomes in HPV-independent versus HPV-associated cervical adenocarcinoma One Type of Cervical Cancer Is Far More Dangerous Than Others
This systematic review and meta-analysis synthesized comparative studies on HPV-independent and HPV-associated cervical adenocarcinoma. It f…
A large new analysis reveals that women with HPV-negative cervical adenocarcinoma face nearly three times the risk of death compared to thos…
Frontiers May 8, 2026